Johnson & Johnson (JNJ)
148.53
-1.03
(-0.69%)
USD |
NYSE |
Apr 24, 16:00
148.53
0.00 (0.00%)
Pre-Market: 20:00
Johnson & Johnson Cash from Financing (Quarterly): -4.655B for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -4.655B |
| September 30, 2023 | -11.32B |
| June 30, 2023 | -5.991B |
| March 31, 2023 | 6.138B |
| December 31, 2022 | 1.70B |
| September 30, 2022 | -3.925B |
| June 30, 2022 | -2.261B |
| March 31, 2022 | -4.385B |
| December 31, 2021 | -3.436B |
| September 30, 2021 | -2.207B |
| June 30, 2021 | -3.279B |
| March 31, 2021 | -5.125B |
| December 31, 2020 | -5.644B |
| September 30, 2020 | 4.196B |
| June 30, 2020 | -357.00M |
| March 31, 2020 | -4.315B |
| December 31, 2019 | -4.072B |
| September 30, 2019 | -3.893B |
| June 30, 2019 | -4.534B |
| March 31, 2019 | -5.516B |
| December 31, 2018 | -6.389B |
| September 30, 2018 | -3.477B |
| June 30, 2018 | -2.674B |
| March 31, 2018 | -5.97B |
| December 31, 2017 | -3.537B |
| Date | Value |
|---|---|
| September 30, 2017 | -2.069B |
| June 30, 2017 | -1.917B |
| March 31, 2017 | -150.00M |
| December 31, 2016 | -3.464B |
| September 30, 2016 | -3.445B |
| June 30, 2016 | -1.038B |
| March 31, 2016 | -604.00M |
| December 31, 2015 | -3.294B |
| September 30, 2015 | -1.84B |
| June 30, 2015 | -2.775B |
| March 31, 2015 | -3.227B |
| December 31, 2014 | -858.00M |
| September 30, 2014 | -5.716B |
| June 30, 2014 | -2.868B |
| March 31, 2014 | -3.057B |
| December 31, 2013 | 1.182B |
| September 30, 2013 | -4.519B |
| June 30, 2013 | -1.977B |
| March 31, 2013 | -777.00M |
| December 31, 2012 | -1.471B |
| September 30, 2012 | -1.653B |
| June 30, 2012 | -16.26B |
| March 31, 2012 | -1.183B |
| December 31, 2011 | -756.00M |
| September 30, 2011 | -2.232B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.32B
Minimum
Sep 2023
6.138B
Maximum
Mar 2023
-3.019B
Average
-3.925B
Median
Sep 2022
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | 2.754B |
| Gilead Sciences Inc | -1.099B |
| Eli Lilly and Co | 3.545B |
| Merck & Co Inc | -2.245B |
| Shockwave Medical Inc | -0.164M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 7.863B |
| Cash from Investing (Quarterly) | -1.202B |
| Free Cash Flow | 17.78B |
| Free Cash Flow Per Share (Quarterly) | 2.387 |
| Free Cash Flow to Equity (Quarterly) | 6.393B |
| Free Cash Flow to Firm (Quarterly) | 5.804B |
| Free Cash Flow Yield | 4.77% |